Similarly, another study demonstrated that the expansion of TCR in melanoma patients from CTLA-4 blockade (tremelimumab) is related to the priming encounter between T cells and APCs in the lymph nodes, whereas the inhibitory signal of PD-1/PD-L1 with PD-1 blockade (pembrolizumab) occurs in peripheral tissues 112. The gene discussed is CTLA4; the disease is melanoma.